Naturally Inspired | Scientifically Defined

Specialist in plant derived cell signalling small molecules to address
challenging medical conditions for humans and companion animals

QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of STELFONTA®

20 January 2020

STELFONTA® (tigilanol tiglate) has been approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment available for all grades of canine non-metastatic mast cell tumours (MCT). The approval marks the first registration of QBiotics' lead compound tigilanol tiglate, which is also under review by the US Food and Drug Administration - Center for Veterinary Medicine (FDA-CVM) and the Australian Pesticides and Veterinary Medicines Authority (APVMA). The approval is supported by a full technical data package focused on safety and efficacy including a pivotal study in 123 canine patients where a single injection of STELFONTA® completely removed (Complete Response) 75% of treated MCT. QBiotics have partnered with Virbac, who will be launching STELFONTA® across key EU markets in the coming months.

PDF documentRead the full news release